A target trial emulation study published in JAMA Network Open found that adult kidney transplant recipients who received remdesivir within seven days of a COVID-19 diagnosis — completing at least three consecutive days of the antiviral therapy — faced lower rates of cardiovascular and kidney complications over the following year than transplant recipients who went untreated with the drug. Nitipong Permpalung, M.D., M.P., noted in the published findings that antiviral treatment initiated promptly may carry protective effects for this patient population that extend well past the acute illness window.

Permpalung, who serves as associate director at the Johns Hopkins Transplant Research Center and was the study's senior author, noted that the findings were intended to ease physician reluctance around offering remdesivir to adult kidney transplant patients when the treatment is deemed clinically appropriate, adding that multiple variables typically factor into treatment decisions for that population. Factors evaluated in that process cover how well the immune system and kidneys are functioning, whether immune-suppressing medications are in use, how those drugs may interact with others, what side effects treatment may bring, and both the point at which COVID-19 occurred and how severe the illness was.

Among the largest datasets assembled on this population, the research extends beyond near-term findings to trace outcomes over time for adult kidney transplant recipients — a dimension that earlier work on antiviral therapy in high-risk patients had largely left unaddressed. Patients in this group are frequently left out of randomised trials because of the health risks they carry.

Spanning nearly four years — from March 2020 through January 2024 — the study drew on records of adult kidney transplant recipients who contracted COVID-19 and were treated across five Johns Hopkins Medicine hospital sites in Maryland, forming the basis for tracking how patients fared over time. Of the 432 adult kidney transplant recipients studied, remdesivir administered over a minimum three-day course fell within the first week of a COVID-19 diagnosis for 177 patients — representing 41 percent of the cohort — while the remaining 255, or 59 percent, went without the antiviral treatment. Participants already taking monoclonal antibodies or other antiviral treatments were left out of the analytical pool.

Two cohorts emerged from the pool of patients enrolled in this simulated trial: one arm received remdesivir administered through an intravenous line, while the other arm went without the treatment. Over the course of twelve months, each patient's progress was tracked and monitored.

Graft loss from any cause served as the study's primary endpoint, encompassing both outright kidney rejection and death regardless of its origin. Among the endpoints tracked as secondary measures were heart-related complications, death attributable to any underlying cause, and the condition now known as long COVID.

Of the 432 adults in the study population, 48 individuals — representing roughly one in nine participants — lost their grafts for any reason. Of the 430 participants, 43 — one in ten — went on to develop a cardiovascular event, whether a heart attack, a stroke, or a death attributed to cardiac causes. Among the 35 patients who died from any cause, that figure represented 8% of the total group studied. Of the 17 people tracked in the study, one in every 25 went on to experience long COVID symptoms.

Controlling for participant variables that included age, pre-existing health conditions, current medications, disease severity, transplant timing, COVID-19 vaccination status, and the date of COVID-19 diagnosis, the research team determined that patients who received remdesivir early in their illness faced a 47% lower probability of all-cause graft loss and a 42% reduced likelihood of cardiovascular events relative to those who went without the antiviral. No statistically confirmed link to lower all-cause mortality emerged from the data, though the numbers did point in that direction. Limitations in the number of patients with a documented long COVID diagnosis meant the analysis on that condition could not yield definitive findings.

A notable share of those enrolled in the study came in carrying pre-existing conditions that placed them at heightened vulnerability, and a portion went on to develop illness that fell in the moderate-to-severe range. Of the 440 adults in the study, 88 — representing one in five — arrived at the point of diagnosis already dependent on supplemental oxygen. Of the group, 413 patients — representing 95% of the total — carried a diagnosis of elevated blood pressure, while diabetes was documented in 199 individuals (46%) and coronary artery disease in a further 63 (15%).

Of the roughly 436 study participants, about 109 — representing one in four — had undergone a kidney transplant in the twelve months preceding their COVID-19 diagnosis. Of the 430 patients reviewed, 254 — representing 59 percent of the total — had discontinued their immunosuppressive medication, the drug prescribed to keep transplanted organs from being attacked by the body's own defences, by the point their COVID infection was recorded.

Of the 433 total participants, 260 — representing roughly three in every five enrolled — contracted COVID-19 during the period when omicron variants of SARS-CoV-2 were the dominant strains in circulation, a stretch that began after 15 December 2021. Of the 427 participants, 145 — accounting for 34 percent — had contracted COVID-19 before the delta variant took hold, a period ending on July 1, 2021. Among the remaining 27 participants, accounting for 6% of the total, their COVID-19 infections were recorded during the delta-variant window that ran from July 2 through December 15, 2021.

A COVID-19 vaccine had been administered to over half of those enrolled in the study. Of the 435 total, three or more doses had been administered to 165 people (38%), while a further 89 (21%) had received between one and two.

Those who received remdesivir tended to be older — a median age of 61 against 54 in the comparison group — and three times as likely to need breathing support, with 33% requiring it versus 11%. The lead study author, Karan Srisurapanont, M.D., offered that several biologically plausible mechanisms could account for these associations, noting that early suppression of viral replication might limit systemic inflammation, injury to the endothelium and blood vessels, and clotting-related complications that can contribute to heart and kidney damage.

The study examined whether remdesivir affected rates of all-cause graft loss in kidney transplant recipients who developed symptomatic COVID-19. The research article, carrying the identifier e2625591, appeared in JAMA Network Open, volume 9, issue 7, published in 2026, under the digital object identifier 10.1001/jamanetworkopen.2026.25591.